NANOBIOTIX : Nanobiotix to present preclinical data on

NANOBIOTIX TO PRESENT PRECLINICAL DATA ON NANOPARTICLE RADIOENHANCER NBTXR3  AT THE AACR ANNUAL MEETING 2017

• Antitumor efficacy of NBTXR3 in different types of tumors - in vivo preclinical data
• Antitumor efficacy of NBTXR3 when combined with chemotherapy - in vitro and in vivo data

Paris, France and Cambridge, Massachusetts, March 7, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C (April 1-5, 2017).

A key part of the non-clinical development stands in building strategies to use NBTXR3 product across oncology as a single agent and in combination with other cancer treatments modalities. An increasing number of cancer models including patient's tumor fragments have been evaluated in vitro and in vivo, with NBTXR3 and radiotherapy, increasing evidence of transferability of antitumor effects within very diverse tumors.

" These NBTXR3 preclinical data highlight the Nanobiotix' nanoparticles potential to treat different types of cancers" said Laurent Levy, CEO of Nanobiotix. "These results reinforce the rationale and level of scientific evidence to reach our long-term goal development of NBTXR3 in most cancer patients candidates to radiation treatment. "

"Hafnium oxide nanoparticles (NBTXR3), a novel radiation enhancer achieves marked antitumor efficacy across five tumor types" Abstract number :17-A-2547

Nanobiotix will present data illustrating the marked anti-tumor efficacy of NBTXR3 with radiotherapy, in in vivo conditions. NBTXR3 showed superiority when compared to the sole use of radiation in soft tissue sarcoma, prostate, head & neck, colorectal and lung cancer models including patient's tumor fragment of prostate adenocarcinoma. These studies also showed NBTXR3 to have intratumor persistence of nanoparticles over time in all evaluated cancer types. In addition, animals tolerated the treatment very well.

"The radioenhancer NBTXR3 brings anticancer efficacy to the cisplatin-based chemoradiation in vitro and in vivo" Abstract number : 17-A-1065

Nanobiotix will also present data highlighting the signs of NBTXR3's antitumor efficacy when combined with cisplatin-based chemoradiation both in vitro and in vivo . Cisplatin is a cytotoxic agent that inhibits DNA repair of sub-lethal damage from irradiation. Chemoradiation of this type is currently the primary treatment for patients with high-risk head and neck cancers, cervix and non-small cell lung cancers. Nanobiotix' in vivo and in vitro results revealed that adding NBTXR3 significantly improves the anticancer effect of the chemoradiation. This research was performed in collaboration with Professor Bo Lu, from the Cancer Center of Thomas Jefferson University in Philadelphia, PA.

***

About American Association for Cancer Research (AACR) www.aacr.org  

The AACR Annual Meeting is one of the main international oncology event highlighting the best cancer science and medicine from institutions all over the world. The American Association for Cancer Research (AACR) Annual Meeting 2017 will take place in Washington, D.C (April 1-5, 2017).

About NANOBIOTIX : www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

Disclaimer This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, forward-looking statements are not guarantees of future performance as they relate to future events and are dependent on circumstances that may or may not materialize in the future, and on a variety of risks and uncertainties, including those set forth in the update of the reference document filed by Nanobiotix with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.16-0732-A01 on December 27, 2016 (a copy of which is available on www.nanobiotix.com) and on the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. Nanobiotix disclaims any responsibility for updating any such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares or other securities in any country. At the present time, NBTXR3 does not bear a CE mark and, consequently, may not be placed on the market or used until such time as a CE mark is obtained.